X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES FRESENIUS KABI ONCO. JUBILANT LIFE SCIENCES/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 15.2 22.1 68.7% View Chart
P/BV x 4.5 3.1 144.3% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 JUBILANT LIFE SCIENCES   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
FRESENIUS KABI ONCO.
Mar-13
JUBILANT LIFE SCIENCES/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs187176 106.1%   
Low Rs6579 82.9%   
Sales per share (Unadj.) Rs364.337.7 966.8%  
Earnings per share (Unadj.) Rs6.85.1 134.4%  
Cash flow per share (Unadj.) Rs24.56.7 364.4%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %2.40-  
Book value per share (Unadj.) Rs164.942.5 387.6%  
Shares outstanding (eoy) m159.28158.23 100.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.4 10.2%   
Avg P/E ratio x18.425.0 73.6%  
P/CF ratio (eoy) x5.118.9 27.2%  
Price / Book Value ratio x0.83.0 25.5%  
Dividend payout %43.80-   
Avg Mkt Cap Rs m20,06120,135 99.6%   
No. of employees `0006.21.2 536.9%   
Total wages/salary Rs m11,052703 1,571.6%   
Avg. sales/employee Rs Th9,383.05,176.2 181.3%   
Avg. wages/employee Rs Th1,786.9610.4 292.7%   
Avg. net profit/employee Rs Th176.3699.6 25.2%   
INCOME DATA
Net Sales Rs m58,0345,963 973.2%  
Other income Rs m19118 1,058.9%   
Total revenues Rs m58,2245,981 973.5%   
Gross profit Rs m5,7861,430 404.6%  
Depreciation Rs m2,812258 1,090.2%   
Interest Rs m3,237-26 -12,450.8%   
Profit before tax Rs m-721,216 -5.9%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,145-68 -3,149.6%   
Tax Rs m696342 203.5%   
Profit after tax Rs m1,090806 135.3%  
Gross profit margin %10.024.0 41.6%  
Effective tax rate %-965.928.1 -3,432.8%   
Net profit margin %1.913.5 13.9%  
BALANCE SHEET DATA
Current assets Rs m29,2805,102 573.9%   
Current liabilities Rs m38,9122,385 1,631.2%   
Net working cap to sales %-16.645.6 -36.4%  
Current ratio x0.82.1 35.2%  
Inventory Days Days84150 56.2%  
Debtors Days Days51113 44.7%  
Net fixed assets Rs m55,7125,148 1,082.2%   
Share capital Rs m155158 97.7%   
"Free" reserves Rs m20,9686,556 319.8%   
Net worth Rs m26,2656,732 390.2%   
Long term debt Rs m17,169952 1,803.1%   
Total assets Rs m88,60610,388 853.0%  
Interest coverage x1.0-45.8 -2.1%   
Debt to equity ratio x0.70.1 462.1%  
Sales to assets ratio x0.70.6 114.1%   
Return on assets %4.97.5 65.1%  
Return on equity %4.212.0 34.7%  
Return on capital %11.614.6 79.2%  
Exports to sales %37.874.5 50.7%   
Imports to sales %16.524.8 66.5%   
Exports (fob) Rs m21,9334,441 493.9%   
Imports (cif) Rs m9,5671,477 647.6%   
Fx inflow Rs m22,0045,298 415.4%   
Fx outflow Rs m11,7491,772 663.0%   
Net fx Rs m10,2553,525 290.9%   
CASH FLOW
From Operations Rs m8,0261,274 629.9%  
From Investments Rs m-1,744-1,204 144.8%  
From Financial Activity Rs m-4,447-196 2,267.9%  
Net Cashflow Rs m1,834-126 -1,452.5%  

Share Holding

Indian Promoters % 45.6 0.0 -  
Foreign collaborators % 3.5 81.0 4.3%  
Indian inst/Mut Fund % 8.7 0.3 2,900.0%  
FIIs % 21.2 9.6 220.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 9.1 231.9%  
Shareholders   23,815 42,599 55.9%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ABBOTT INDIA  NATCO PHARMA  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 150 Points Higher; Banking Stocks Witness Buying(Closing)

Indian share markets continued their momentum and ended the day on a positive note. Gains were largely seen in the banking sector, consumer durables sector and realty sector.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY19); Net Profit Up 67.2% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 67.2% YoY). Sales on the other hand came in at Rs 23 bn (up 38.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Dec 13, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS